Clinical Trial

A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 10, 2024 (before its estimated December 4, 2024 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to compare the efficacy and safety of GR2001 injection with Human Tetanus Immunoglobulin(HTIG) in tetanus prophylaxis. Patients will receive either GR2001 injection or HTIG on study D0.
Trial Details
NCT Number NCT06635798
Lead Sponsor Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions Tetanus
Enrollment 582 participants
Start Date 2024-09-03
Primary Completion 2024-12-04 (estimated)
Study Completion 2025-03-04 (estimated)
Updated on ClinicalTrials.gov 2024-10-10